Marion Delenclos
Mayo Clinic
23 Papers
4 Citations
Marion Delenclos is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Synucleinopathies & Alpha-synuclein. The author has an hindex of 9, co-authored 17 publications.
Chat about Author
Papers
Alpha-synuclein and tau: teammates in neurodegeneration?
Simon Moussaud,Daryl R. Jones,Elisabeth L. Moussaud-Lamodière,Marion Delenclos,Owen A. Ross,Pamela J. McLean +5 more
TL;DR: It is suggested that interactions between tau and α-synuclein form a deleterious feed-forward loop essential for the development and spreading of neurodegeneration.
Biomarkers in Parkinson's disease: Advances and strategies.
TL;DR: This review summarizes recent advances in the development of PD biomarkers and discusses new strategies for their utilization.
176
Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway
Jae Hyeon Park,Jeremy D. Burgess,Ayman H. Faroqi,Natasha N. DeMeo,Fabienne C. Fiesel,Wolfdieter Springer,Marion Delenclos,Pamela J. McLean +7 more
TL;DR: It is demonstrated that αsyn associates with mitochondria and induces a decrease in mitochondrial SIRT3 levels and mitochondrial biogenesis, which suggests that pharmacologically increasing Sirt3 levels can counteract αsyn-induced mitochondrial dysfunction by reducing αsyn oligomers and normalizing mitochondrial bioenergetics.
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid.
Na Zhao,Olivia N. Attrebi,Yingxue Ren,Wenhui Qiao,Berkiye Sonustun,Yuka A. Martens,Axel D. Meneses,Fuyao Li,Francis Shue,Jiaying Zheng,Alexandra J. Van Ingelgom,Mary D. Davis,Aishe Kurti,Joshua Knight,Cynthia Linares,Yixing Chen,Marion Delenclos,Chia Chen Liu,John D. Fryer,Yan W. Asmann,Pamela J. McLean,Dennis W. Dickson,Owen A. Ross,Guojun Bu +23 more
TL;DR: A pathogenic role of APOE4 is demonstrated in exacerbating α-synuclein pathology independent of amyloid, providing mechanistic insights into how APOE2 or APOE3 increases the risk of LBD.
127
CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage
Jichao Sun,Jared Carlson-Stevermer,Utpal Das,Minjie Shen,Marion Delenclos,Amanda M. Snead,So Yeon Koo,Lina Wang,Dianhua Qiao,Jonathan Loi,Andrew J. Petersen,Michael E. Stockton,Anita Bhattacharyya,Mathew V. Jones,Xinyu Zhao,Pamela J. McLean,Andrew Sproul,Krishanu Saha,Subhojit Roy +18 more
TL;DR: A CRISPR/Cas9-based strategy to selectively edit the C-terminus of APP and attenuate amyloid-β production, while upregulating neuroprotective α-cleavage is described.